Amgen, Inc. AMGN - Invitrogen 2Q Profit Rises and Amgen Wins Patents Appeal and Amorfix and Biogen to Collaborate on ALS
Invitrogen 2Q Profit Rises and Amgen Wins Patents Appeal and Amorfix and Biogen to Collaborate on ALS
City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/04/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Advanced lab research equipment and services company Invitrogen Corp. (Nasdaq:IVGN) said Thursday its second-quarter profit jumped 32 percent as it lowered expenses and posted a gain from the sale of its German manufacturing business. The company earned $19.7 million, or 36 cents per share, compared with $14.9 million, or 27 cents per share, a year ago. Pro forma results, which exclude charges and gains from acquisitions and stock option expensing, were 90 cents per share. Amgen Inc. announced Thursday that the Court of Appeals for the Federal Court affirmed a previous decision that Amgen's (Nasdaq:AMGN) erythropoietin (EPO) patent estate was infringed by Transkaryotic Therapies Inc. and Aventis Pharmaceuticals. The appeal reviewed the District Court's findings on the infringement and validity of two patents with claims to the production of erythropoietin; the infringement of one patent under the doctrine of equivelents; and the validity of one product patent.
Biotech Company Amorfix Life Sciences Ltd. said Thursday it struck a research and investment deal with U.S.-based Biogen Idec. (Nasdaq:BIIB) The Toronto company said the deal with Biogen of Cambridge, Mass., includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic treatments for Amyotrophic Lateral Sclerosis, a neurodegenerative condition also known as Lou Gehrig's Disease. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/04/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Advanced lab research equipment and services company Invitrogen Corp. (Nasdaq:IVGN) said Thursday its second-quarter profit jumped 32 percent as it lowered expenses and posted a gain from the sale of its German manufacturing business. The company earned $19.7 million, or 36 cents per share, compared with $14.9 million, or 27 cents per share, a year ago. Pro forma results, which exclude charges and gains from acquisitions and stock option expensing, were 90 cents per share. Amgen Inc. announced Thursday that the Court of Appeals for the Federal Court affirmed a previous decision that Amgen's (Nasdaq:AMGN) erythropoietin (EPO) patent estate was infringed by Transkaryotic Therapies Inc. and Aventis Pharmaceuticals. The appeal reviewed the District Court's findings on the infringement and validity of two patents with claims to the production of erythropoietin; the infringement of one patent under the doctrine of equivelents; and the validity of one product patent.
Biotech Company Amorfix Life Sciences Ltd. said Thursday it struck a research and investment deal with U.S.-based Biogen Idec. (Nasdaq:BIIB) The Toronto company said the deal with Biogen of Cambridge, Mass., includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic treatments for Amyotrophic Lateral Sclerosis, a neurodegenerative condition also known as Lou Gehrig's Disease. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
posted by Famous Quotations - Amgen, Inc. AMGN - Invitrogen 2Q Profit Rises and Amgen Wins Patents Appeal and Amorfix and Biogen to Collaborate on ALS
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home